1. Overview – the in-vitro to ex-vivo to in-vivo paradigm
1. In-vitro - importance of choosing suitable cell lines
2. Ex-vivo – adding the complexity of in-vivo background while keeping the simplicity of in-vitro
3. In-vivo - all the complexity of ex-vivo plus the “active” components of a real animal
2. In-vivo systems are open, “active” systems with multiple layers of complexity
1. In-vitro and ex-vivo are mostly “closed” systems, but not absolutely
2. What is an “open” system?
3. Attempts to isolate open systems
3. Layers of complexity of in-vivo systems
1. Human cells in nude mice – a mixture of in-vitro and in-vivo
2. “Model” small animal systems
3. Bbetter model larger animal systems
4. Examples of the in-vitro to in-vivo experimental pathway
1. Kopelman group – multifunctional NPs for MRI and photodynamic therapy
2. Langer group – aptamer-targeted NPs for cancer therapy in-vivo
3. Leary group – peptide-guided NPs to human tumors in nude mice magnetic nanoparticles as MRI contrast agents in tissue phantoms

• Kopelman, R., Koo, Y-E, Philbert, M., Moffatc, B.A., Reddy,G.R., McConville, P., Hall, D.E., Chenevert, T.L., Bhojanie, M.S., Buck, S.M., Rehemtulla, A., Ross, B.D. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. Journal of Magnetism and Magnetic Materials 293: 404–410, 2005.
• Farokhzad, O.C., Cheng, J., Teply, B.J., Sherifi, I., Jon, S., Kantoff, P.W., Richie, J.P., Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. PNAS 103(16), 6315–6320, 2006

If you reference this work in a publication, please cite as follows:

• Leary, James (2007), "BME 695N Lecture 18: Designing nanodelivery systems for in-vivo use," http://www.nanohub.org/resources/3515/.

  BibTex | EndNote

1. cancer
2. course lecture
3. drug delivery
4. nanomedicine